Dupilumab in chronic obstructive pulmonary disease: a pooled analysis of emergency department visits, hospital admissions, and systemic corticosteroid use.
Am J Respir Crit Care MedSep 1, 2026
Surya P Bhatt, Fernando J Martinez, Imran Satia et al.
✦ AI-curated · Sources linked
In 30 seconds
This pooled analysis from two phase III randomized controlled trials evaluated the impact of dupilumab on emergency department visits, hospital admissions, and systemic corticosteroid use in patients aged 40-85 with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. Dupilumab reduced ED visits/hospital admissions by 38% and systemic corticosteroid use during severe exacerbations by 42% compared to placebo.
Key findings
- Dupilumab reduced ED visits/hospital admissions by 38% (rate ratio, 0.62; P = .0121).
- Time to first ED visit/hospital admission was delayed with dupilumab treatment.
- Systemic corticosteroid use was reduced by 42% during severe exacerbations (rate ratio, 0.58; P = .0126).
- Moderate exacerbations saw a 28% reduction in corticosteroid use (rate ratio, 0.72; P = .0005).
Why it matters
The findings suggest that dupilumab may significantly reduce acute healthcare utilization and corticosteroid exposure in COPD patients, addressing both clinical stability and long-term treatment concerns associated with exacerbations.